Biomedical Advanced Research and Development Authority (BARDA)

Rapid Response Partnership Vehicle (RRPV)

Request for Project Proposals (RPP)

Solicitation Number: RRPV 26-10-RAPID

"Rapid Antibody Production for Immunoassay Diagnostics"

Request Issue Date: 15 APRIL 2026
Due Date: 13 MAY 2026 by 1pm Eastern

Biomedical Advanced Research and Development Authority (BARDA)
Contracts Management & Acquisition (CMA)
400 7th Street, SW, Washington, DC 20024
MedicalCountermeasures.gov

1 Executive Summary

1.1 Rapid Response Partnership Vehicle Consortium

The Rapid Response Partnership Vehicle (RRPV) Consortium is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities, in cooperation with the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services (HHS).

The RRPV will help fortify national health security by developing medical countermeasure products prior to and during a pandemic or public health emergency. The RRPV will focus on the acceleration of products and technology development, regulatory approval, commercialization, and sustainment to address pandemic influenza, emerging infectious diseases, and other biological threats.

Advanced Technology International (ATI) has been awarded an Other Transaction Agreement (OTA) by BARDA to serve as the Consortium Management Firm (CMF) for the RRPV.

RRPV is openly recruiting members to join a broad and diverse biomedical consortium that includes representatives from all organizations who work within stated technical focus areas. For more information on the RRPV mission, refer to the RRPV website at RRPV.org. For entities interested in joining the RRPV Consortium and responding to this solicitation, please visit http://www.rrpv.org/how-to-join.

1.2 Background

Emerging infectious diseases, engineered biological threats, and rapidly evolving pathogen variants continue to pose significant risks to national health security. Immunoassay diagnostics are central to outbreak response and medical countermeasure deployment; however, a major bottleneck in domestic diagnostic production and commercialization is the design, development, and manufacture of highly specific antibodies and other protein-based molecular recognition reagents. Using conventional methods, this process can take a year or longer, creating a critical gap between pathogen identification and the availability of deployable tests.

Recent public health emergencies have underscored the need for a rapid, scalable, and repeatable capability to generate assay-ready reagents shortly after pathogen genomic information becomes available. Traditional animal immunization timelines, labor-intensive screening workflows, and limited surge manufacturing capacity of critical reagents together slow diagnostic development and constrain response speed. Further, dependence on complex and often foreign supply chains increases vulnerability during public health emergencies.

To address these challenges, the Government seeks to establish a US-based rapid antibody production capability that can be readily adapted to any emerging infectious disease or biological threat, significantly compressing timelines from sequence release to immunoassay-ready reagents. This effort aims to leverage recent advances in technologies like AI-enabled and *de novo* binder design, in silico epitope modeling and candidate optimization, next-generation synthetic and recombinant libraries, advanced display and selection systems, and high-throughput automated screening and characterization platforms to create an integrated end-to-end solution, capable of going from threat gene sequence to manufactured high specific and sensitive antibody (or protein-based molecular recognition reagents) within weeks.

By tightly coupling computational and experimental workflows, the program seeks to remove key bottlenecks across discovery, down-selection, optimization, and production of antibodies (or other protein-based molecular recognition reagent) to significantly accelerate delivery of high-performance immunoassay reagents and enhance diagnostic readiness and supply chain resilience to prepare for future

biological threats.

1.3 Purpose

The purpose of this RPP is to support advanced research and development of rapid antibody or other protein-based molecular recognition reagents generation platforms to enable timely production of immunoassay-ready reagents to detect viral and bacterial pathogens for eventual use in diagnostics. BARDA seeks highly flexible, rapidly adaptable systems capable of generating high-performance binders against pathogens, both known or previously unknown biological threats during public health emergencies.

Proposed solutions should demonstrate advanced capabilities in protein and binder design and discovery - including computational, AI-enabled, and high-throughput experimental approaches - integrated with downstream optimization and production, with a clear pathway to GMP quality. The objective is to substantially compress development timelines, ideally enabling delivery of purified, assay-ready antibodies or other protein-based molecular recognitions reagents within weeks. While manufacturing is not expected to be the primary focus, both laboratory-scale and flexible production models are of interest, provided they can reliably generate at scale for diagnostic use within compressed timelines, faster than traditional workflows, ideally within weeks rather than months following receipt of the target pathogen genome sequence.

2 Administrative Overview

2.1 RPP Approach

A multi-stage approach will be employed to streamline the process for preparation, submission, evaluation, and notification. A down selection will occur between Stages 1 and 2. Participation in Stage 1 does not guarantee the opportunity to submit a Full Technical and Cost Proposal in Stage 2, and submission of a Full Technical and Cost Proposal in Stage 2 does not guarantee an award. Each stage of this solicitation process is competitive. Successful offerors will be invited to participate in the next stage of the process via email from the RRPV Consortium Management Firm (CMF) following the results of the evaluation. Invitation to negotiations at any stage does not guarantee an award. Submissions that are not selected to proceed beyond Stage 1 or Stage 2, including the basket (see Section 5.5/5.6 below) will receive notification, but may not receive feedback.

The solicitation stages are as follows:

Stage 1 - Abstract

In Stage 1, Offerors will submit an Abstract and a 1-page Quad Chart. Abstracts submitted under this RPP shall follow the mandatory templates provided in Attachment 1. BARDA will evaluate the Stage 1 Abstracts to determine which proposed solutions best meet the evaluation criteria as well as BARDA's current technology priorities and program objectives. Those Offerors invited to proceed to Stage 2 will be provided feedback, particularly focusing on needed clarifications to be addressed in the Stage 2 submission. Offerors who are not invited to proceed into Stage 2 will be notified by the CMF.

Stage 2 - (By Invitation Only) Full Technical Proposal & Cost Proposal

The successful Stage 1 Offeror(s) will receive an invitation letter/email from the CMF to submit a full technical proposal and cost proposal. Stage 2 is anticipated to require a Technical Proposal, Cost Proposal Narrative, Cost Proposal Format, and Statement of Work. Further instructions will be provided to successful Stage 1 Offerors in the invitation notification.

2.2 Order of Precedence

Each proposal selected for award under this RPP will be executed as a Project Award under the RRPV Base Agreement 75A50123D00005. The same provisions will govern this Base Agreement as the OTA between the U.S. Government (USG) and ATI ("RRPV Base") unless otherwise noted in the Project Award.

2.3 Period of Performance and Funding

2.3.1 Period of Performance

BARDA estimates the full program Period of Performance to be up to two (2) years from date of award. Specific dates will be negotiated prior to award of the project agreement and may extend beyond 2 years. It is anticipated that the primary place of performance will be the performers' facilities, however this requirement can be negotiated as part of each Performers' submission.

2.3.2 Funding

The total USG funding amount anticipated to be available for Project Awards is approximately $15-20M, and the USG anticipates making up to 5-6 awards. Award and funding from the Government is contingent upon the availability of federal funds for this program. The funding estimated for this RPP is approximate and subject to realignment.

2.4 Expected Award Date

Offeror should plan on the period of performance beginning during the fourth quarter of calendar year 2026. Government reserves the right to change the proposed period of performance start date through negotiations via the RRPV CMF and prior to issuing a Project Award.

2.5 Proprietary Information

The RRPV CMF will oversee submission of abstracts and proposals submitted in response to this RPP. The RRPV CMF shall take the necessary steps to protect all proprietary information and shall not use such proprietary information for purposes other than proposal evaluation and agreement administration. Please mark all Confidential or Proprietary Information as such. An Offeror's submission of a response under this RPP indicates concurrence with the aforementioned CMF responsibilities.

2.6 Mandatory Eligibility Criteria

In order to be eligible for consideration, Offerors (and facilities used in this proposal) must be US-based and be RRPV members when their Abstract is submitted. Prospective Offerors may join the consortium at www.rrpv.org/how-to-join.

Abstracts found to not meet minimum eligibility criteria(s) as detailed above may be removed from consideration, no further evaluation will be performed, and feedback will not be provided to these Offerors.

2.7 Cost Sharing

Cost sharing is defined as the resources expended by the Project Awardee on the proposed Statement of Work (SOW). Cost sharing is encouraged, if possible, as it leads to stronger leveraging of Government-Performer collaboration but is not required.

2.8 Intellectual Property and Data Rights

Intellectual Property (IP) rights for RRPV Project Awards will be defined in the terms of a Project Awardee's Base Agreement. The RRPV CMF reserves the right to assist in the negotiation of IP, royalties, licensing, future development, etc., between the Government and the Project Awardees during the entire award period.

The Offeror shall comply with the terms and conditions defined in the RRPV Base Agreement regarding Data Rights**. It is anticipated that anything delivered under this proposed effort would be delivered to the Government with unlimited data rights as defined in the RRPV Base Agreement unless otherwise specified in Attachment 1, Abstract, and agreed to by the Government.** All proposed data rights are subject to Government review and approval. Rights in technical data agreed to by the Government will be incorporated into the Project Award.

3 Submissions

3.1 Question and Answer Period

Key dates related to this RPP are provided below. Please submit questions to Ms. Kathy Garee (rrpv-contracts@ati.org). Answers will be posted publicly to the RRPV website.

Date	Event	Method
15 April 2026	RPP Released	RRPV Website
27 April 2026	Proposers Conference	Zoom
30 April 2026, 12pm ET	Questions Due	Email to rrpv-contracts@ati.org
4 May 2026	Answers Released (Approximate)	RRPV Website
13 May 2026, 1pm ET	Abstracts Due	RRPV BDR Portal

3.2 General Instructions

The formats provided in this RRPV RPP are mandatory and shall reference this RPP number. ***At the time of the submission, Offerors must certify on the cover page of their Abstract that, if selected for award, they will abide by the terms and conditions of the latest version of the RRPV Base Agreement*.** Offerors may request a current copy of the RRPV Base Agreement terms and conditions by emailing RRPV-contracts@ati.org. Base Agreements are typically not executed until Offeror is selected for award.

Offerors are encouraged to contact the Point of Contact (POC, see Section 6), identified herein up until the submission date/time to clarify requirements.

Abstracts and Quad Chart shall reference this RPP number. The Abstract and Quad chart is mandatory and shall remain valid for 180 days unless otherwise specified by the Offeror in the submission. Offerors are

encouraged to contact the RRPV CMF with any questions so that all aspects are clearly understood by both parties.

All eligible Offerors shall submit Abstracts and Quad charts for evaluation according to the criteria set forth in this RPP. Offerors are advised that only ATI, as the RRPV's CMF, with the approval of the Other Transaction Agreements Officer, is legally authorized to contractually bind or otherwise commit funding for selected Project Awards as result of this RPP.

3.3 Abstract and Quad Chart Submission

Abstracts and Quad Charts shall be submitted by the date and time specified on the cover page to the BARDA Digital Resource (BDR) portal website at https://rrpv.hhs.gov/. Abstracts received after the date and time specified may not be evaluated.

Offerors will be required to register for a BDR portal account before a response can be submitted. A BDR account can be requested by contacting ATI at RRPV@ati.org. The account request process is simple but may take several days for approval and access. Upon confirmation of a BDR portal account, the Offeror will login using the prescribed two-factor authentication method.

Offerors are strongly encouraged to access the BDR Portal well in advance of the submission due date to verify their ability to log in, confirm account validity, and ensure full access to the submission system. Failure to submit on time for any reason (e.g., due to late registration in BDR portal) will result in the submission not being considered for award. Offerors will be provided an automated confirmation of successful submission.

Do not submit any classified information in the Abstract or Quad Chart submission.

3.4 Preparation Cost

The cost of preparing Abstracts, Quad Charts, and/or Proposals in response to this RPP is not considered a direct charge to any resulting award or any other contract.

3.5 Submission Format

Stage 1 submissions shall consist of a written Abstract of no more than five (5) pages and a Quad Chart of no more than one (1) page, prepared in accordance with the template and formatting instructions in Attachment 1. Submissions exceeding the page limits or not adhering to the prescribed format may be rejected without further review.

4 Technical Requirements

4.1 Introduction

The Offeror shall clearly state how it intends to meet and, if possible, exceed the technical requirements. Mere acknowledgement or restatement of the requirements is not acceptable, unless specifically stated otherwise. These requirements should be addressed in a submitted Abstract. Please note that the Abstract does not include a Statement of Work (SOW). A high-level schedule that groups critical tasks and discussion in the Technical Approach that addresses the points below will suffice.

4.2 Program Scope and Structure

This program will have a base period that is broken into two phases, 1) Concept Demonstration and 2) a full speed Sprint Test. Final awards are likely to include potential options for additional Sprint Tests to provide reagent development support to new or ongoing diagnostic efforts (e.g. DxR2). Potential Options should not be included in Stage 1 submissions.

As part of the base period, offerors will complete advanced R&D work, integrate, and demonstrate a rapid antibody/binder generation platform capable of delivering immunoassay-ready reagents within compressed timelines following receipt of the genetic sequence of an emerging biological threat. From the pathogen gene sequence, the platform will be able to complete design and discovery, screening, optimization and production.

The program emphasizes end-to-end integration, speed, scalability, and transition readiness. Platforms must produce antibodies/binders that are compatible with common immunoassay formats (e.g. lateral flow, ELISA, chemiluminescent platforms), support surge production, and provide data packages suitable for technology transfer to diagnostics manufacturers.

The base period of this effort will include 2 phases:

Phase 1 – Concept Demonstration: includes R&D work, process development, and demonstration of the integrated platform within the target 2-year period of performance. The Phase 1 Capstone will be a pressure-test where offerors will produce antibody/binders against USG selected organisms/infectious agents (three BSL2 target genomes; viruses, bacteria, and/or fungi). Functional performance will be evaluated against a standard assay format (e.g. ELISA; further information in Stage 2 invitation) and compared against performance of other teams – primarily binder performance, but also delivery time. Further information will be provided to those invited to submit a Stage 2 proposal. However, target specific performance metrics will be provided upon disclosure of challenge target(s) during the performance of the program.

Phase 2 Sprint Test: includes a full speed sprint test against a USG selected target (BSL3) that will be independently verified by a third party. Evaluations will be conducted on a standard assay format (e.g. ELISA) and compared against performance of other performers on the basis of binder performance and delivery time. Performance metrics will be provided upon disclosure of challenge target(s) at the beginning of the sprint test. **Please note, third party testing timelines are outside of your control and therefore unknown. To ensure consistency, assume will require three (3)**

additional months for evaluation and closeout.



Please ensure that high-level schedule and ROM cost of the base period of performance is complete and accounted for in the submission.

4.3 Performance Objectives

Proposed antibody/binder generation platforms should provide an integrated end-to-end capability spanning design and discovery through production of purified, assay-ready, high-affinity, high-specificity antibodies or alternative protein-based molecular recognition reagents as well as reproducible performance across viral, bacterial, and fungal pathogens. The platform should generate new binders within significantly compressed timelines compared to traditional workflows following receipt of that target pathogen genome sequence.

Abstracts must include feasibility data that demonstrate the maturity and technical readiness of each component technology or system. Provide clear descriptions of the platform architecture, workflow, automation level, and timelines achieved to date – overall and for each component. For each major component (e.g., antigen design/production, binder discovery, screening, optimization, purification, and scale-up), offerors must provide feasibility data demonstrating best to date performance including key performance metrics (e.g., K_d, binding kinetics, sensitivity, specificity, throughput rate, cycle time, yield). Benchmarks used to demonstrate time savings relative to traditional workflows should be clearly defined and supported by empirical date from prior efforts where possible. Abstracts must also include representative functional performance data, including preliminary analytical or non-clinical data demonstrating antibody/binder performance. Offerors are encouraged to include data in addition to best to date performance that also demonstrates the flexibility of the platform across a diverse set of targets. Key examples should be concisely summarized in text (e.g. target, binder affinity/avidity, development timeline, purity, specificity), with selected references as appropriate. If possible, provide examples spanning viral, bacterial, and fungal targets.

Offerors must describe R&D activities required to achieve target specifications and fully integrate components into a cohesive end-to-end workflow. Additionally, offerors must include a clear technical validation strategy to demonstrate binder performance, including quantitative metrics such as affinity,

association/dissociation rates, specificity and cross-reactivity testing against related pathogens or relevant background organisms, stability, and yield data. Offerors should also describe any anticipated optimization work and how iterative design-build-test cycles will be performed to meet defined performance targets within the proposed timeline.

For the capstone test, successful assays will demonstrate functional performance in using at least one standard immunoassay format or protocol (e.g., ELISA, lateral flow, chemiluminescent assay; further information in Stage 2 invitation), including preliminary performance metrics such as limit of detection, signal-to-noise ratio, dynamic range, reproducibility, and matrix compatibility using at least one clinically relevant specimen type. The validation plan should describe how discovery outputs will be transitioned into assay-compatible formats (e.g., conjugation, labeling, pair selection) and how down the line assay integration risks will be mitigated. Platforms that can support rapid prototype assay development and provide standardized data packages suitable for transfer to diagnostic developers are preferred.

4.4 Out of Scope Topics

Abstracts on the following topics will be considered out of scope:

- Development of complete diagnostic devices or commercial test kits
- Clinical validation studies or regulatory submission activities
- Programs targeted toward vaccine or therapeutic antibody development
- Nucleic acid-based binders (e.g., aptamers)

Abstracts determined to be out of scope as detailed above may be removed from consideration, no further evaluation will be performed, and feedback will not be provided to these Offerors.

4.5 Gain-of-Function Research

In accordance with Executive Order "Improving the Safety and Security of Biological Research," BARDA does not support gain-of-function research or research involving the manipulation of pathogens that may result in a gain of function.

For purposes of this RPP, gain-of-function research is defined as scientific research on an infectious agent or toxin that has the potential to cause disease by enhancing its pathogenicity or increasing its transmissibility.

Covered research activities include those that could result in significant societal consequences and that seek or achieve one or more of the following outcomes:

- Enhancing the harmful consequences of an agent or toxin
- Disrupting beneficial immunological responses or reducing the effectiveness of immunizations
- Conferring resistance to clinically or agriculturally useful prophylactic or therapeutic interventions, or enabling evasion of detection methodologies
- Increasing the stability, transmissibility, or dissemination potential of an agent or toxin
- Altering the host range or tropism of an agent or toxin
- Enhancing the susceptibility of a human population to an agent or toxin
- Generating or reconstituting an eradicated or extinct agent or toxin

Abstracts and Proposals will be evaluated by BARDA for the appropriate use of strains in proposed studies, in addition to all other evaluation factors. Proposals that include gain-of-function research will be considered unacceptable and will not be eligible for award.

5 Selection/Evaluation

5.1 Compliance Screening

The RRPV CMF will conduct a preliminary screening of submitted Abstracts to ensure compliance with the RPP requirements. As part of the preliminary screening process, submissions that do not meet the requirements of the RPP may be eliminated from the competition or additional information may be requested by the RRPV CMF. The Government reserves the right to request additional information, perform a pre-award audit, or eliminate from further consideration Abstracts that do not meet these requirements

5.2 Evaluation Process

Following the preliminary screening by the CMF for compliance with the RPP requirements, BARDA will perform an evaluation of all eligible Stage 1 Abstracts. Only selected offerors will move on to Stage 2. Feedback may not be provided after each Stage or award.

Stage 1

The criteria will be as follows with elements 1, 2, 3 and 4 of equal importance and element 5 of lower, but substantive importance.

1) Relevance to SOO
2) Innovation/Technical Merit (High-level only)
3) Feasibility (General only)
    a. Confidence in approach
4) Potential impact or benefit
5) Rough budget estimate

Given the limited page-count, the evaluation of Stage 1 Abstracts will be primarily focused on the Technical Approach. Offerors must include all elements in the provided template but are recommended to emphasize a clear Technical Approach supported by preliminary data.

Stage 2

The criteria will be as follows in descending order of importance:

1) **Technical Approach:** The Government will evaluate the extent to which the proposed solution addresses the stated problem and advances the program's objectives. It will further evaluate the degree to which the proposed technology represents an innovative, novel, or disruptive approach relative to the current state of the art.

2) **Technical Feasibility:** The Government will assess the soundness, feasibility, and completeness of the proposed technical approach and development plan to include the quality and relevance

of the provided feasibility data, the proposer's qualifications, expertise, and ability to execute the proposed work.

3) **Cost Reasonableness:** The Government will evaluate the reasonableness of the proposed budget in relation to the scope of work. The Government reserves the right to select proposals that offer the greatest overall value and potential impact, even if they involve higher technical risk.

Innovative or unconventional approaches that demonstrate high potential benefit are encouraged. Proposals will not be penalized for proposing novel technical approaches provided feasibility data is presented and risks and mitigations are appropriately addressed in the technical approach.

Qualified Proposals will be evaluated by a panel of subject matter experts (SMEs) who will make recommendations of whether or not to place a Proposal in the basket. This process may involve the use of contractors as SME consultants or reviewers. Where appropriate, the USG will employ non-disclosure agreements to protect information contained in the RPP. An Offeror's submission of an Abstract and/or Proposal under this RPP indicates concurrence with the aforementioned use of contractors and SMEs.

5.3 Cost/Price Evaluation

Successful Stage 1 Offerors will be invited to submit full proposals. Full proposal templates and instructions will be provided to successful Stage 1 Offerors at time of notification. If a full proposal is selected for award, the RRPV CMF will evaluate the estimated cost proposed by the Offeror for performing all requirements outlined in this RPP. Evaluation will include analysis of the proposed cost together with all supporting information. The RRPV CMF will request additional information or clarification as necessary. The RRPV CMF will assess the reasonableness and completeness of the cost estimates and then provide a formal assessment to the Government. The Government will review this assessment and make the final determination that the project value is fair and reasonable, subject to final Government negotiations.

Stage 2 Cost Proposals will be evaluated using the understanding of cost realism, reasonableness and completeness as outlined below:

a) Realism. Proposals will be evaluated to determine if Costs are realistic for the work to be performed, reflect a clear understanding of the requirements, and are consistent with the various elements of the Offeror's schedule proposal.

Estimates are "realistic" when they are neither excessive nor insufficient for the effort to be accomplished. Estimates must also be realistic for each phase of the proposed project when compared to the total proposed cost.

The RRPV CMF will make a determination by directly comparing proposed costs with comparable current and historical data, evaluator experience, available estimates, etc. Proposed estimates will be compared with the corresponding technical proposals for consistency.

b) Reasonableness. The Offeror's cost proposal will be evaluated to determine if it is reasonable. For a price to be reasonable, it must represent a price to the Government that a prudent person would pay in the conduct of competitive business. Normally, price reasonableness is established through cost and price analysis.

To be considered reasonable, the Offeror's cost estimate should be developed from applicable historic cost data. The Offeror should show that sound, rational judgment was used in deriving and applying cost methodologies. Appropriate narrative explanation and justification should be provided for critical cost elements. The overall estimate should be presented in a coherent, organized and systematic manner.

Costs provided shall be clearly attributable to activities or materials as described by the Offeror. Costs should be broken down in the Cost Proposal Format. An optional template is located on the Members-Only RRPV website.

c) Completeness. The RRPV CMF will evaluate whether the proposal clearly and thoroughly documents the rationale supporting the proposed cost and is compliant with the requirements of the solicitation.

The proposal should clearly and thoroughly document the cost/price information supporting the proposed cost in sufficient detail and depth. The RRPV CMF will evaluate whether the Offeror's cost proposal is complete with respect to the work proposed. The RRPV CMF will consider substantiation of proposed cost (i.e., supporting data and estimating rationale) for all elements.

Rate and pricing information is required to properly perform the cost analysis of the proposal. If the Offeror is unwilling to provide this information in a timely manner, its proposal will be lacking information that is required to properly evaluate the proposal and the proposal may not be selected for award.

5.4 Best Value

The Government will evaluate proposals based on the criteria listed above. The overall award decision will be based upon a Best Value determination by considering and comparing factors in addition to cost or price. Funding recommendations depend on various factors and programmatic relevance. Based on the evaluation, the Government reserves the right to negotiate and request changes to any or all parts of the SOW. Offerors will have the opportunity to concur with the requested changes, propose further changes and revise cost proposals, as necessary.

5.5 Evaluation Results

Following the evaluation of the Stage 2 proposals, BARDA may:

1. Recommend the proposal (or some portion of the proposal) for award;
2. Place the proposal in the Basket; or
3. Reject the proposal (will not be considered for award and will not be placed in the Basket)

The Government does not guarantee a minimum or maximum number of awards resulting from this solicitation.

5.6 Basket Provision

The electronic "Basket" is an innovative acquisition tool. Stage 1 Abstracts or Stage 2 Full Technical and Cost Proposals recommended but not immediately selected for award, may be placed in the Basket for 2 years and eligible for award during that time. Proposals not recommended for the basket will not be placed in the Basket and will not be eligible for future award. If awarding from the Basket, the Government reserves the right to award whichever proposal best meets its needs.

6 Points of Contact

Questions related to this RPP should be directed to Ms. Kathy Garee (rrpv-contracts@ati.org).

All technical questions must be submitted by **April 30, 2026, 12PM ET** to allow for Government response. The Government will respond to questions at its discretion. All questions and responses will be posted to the RRPV Solicitation webpage https://www.rrpv.org/opportunities/. Questions received after the stated deadline are not guaranteed a response.

Once an Offeror has submitted a submission under this RPP, the Government and the RRPV CMF will not discuss evaluation/status until the evaluation results have been provided to the Offerors.

ATTACHMENT 1 – ABSTRACT TEMPLATE

General Instructions

The Abstract must address the technical requirements described in the RPP in sufficient detail to permit evaluation from a technical perspective in accordance with the evaluation factors set forth in the RPP. Offerors are strongly encouraged to use pictures and graphics to succinctly represent proposed ideas, organization, etc.

The Abstract shall be limited to 5 pages **and** Quad Chart limited to 1 page; however, the Cover Page, Period of performance and high-level schedule breakdown for key tasks, Budget Estimation, Data Rights Assertions, and references are not included in the page count. Pages in excess of this limitation may not be considered**.** Offerors are advised that the number of pages should be commensurate with the degree of complexity of the proposed effort.

The following formatting requirements apply:

- 12-point font (or larger), single-spaced, single-sided, 8.5 by 11 inches
- Smaller type may be used in figures and tables, but must be 8-point font (or larger)
- Margins on all sides (top, bottom, left, and right) should be at least 1-inch
- Submit files in Microsoft Word, Adobe Acrobat (PDF – portable and searchable document format) formats. ZIP files and other application formats are not acceptable. All files must be print-capable and without a password required. Filenames shall contain the appropriate filename extension (e.g., .docx or .pdf). Filenames should not contain special characters. iOS users must ensure the entire filename and path are free of spaces and special characters. Movie and sound file attachments or other additional files, will not be accepted.

To ensure Abstracts receive proper consideration, **the format shown below is mandatory**. If there are any items which are not applicable to a specific Abstract, include the section topic in the Abstract with a short explanation as to why it is not applicable.

- Cover page (not included in page count, 1-page limit)
- Executive Summary
- Technical approach narrative with preliminary data
- Teaming/subcontractors
- Facilities and personnel qualification
- Period of performance and high-level schedule breakdown for key tasks (not included in page count, 0.5-page limit)
- Budget estimation (not included in page count, 0.5-page limit)
- Quad Chart (not included in page count, 1-page limit)
- Data Rights Assertions (as needed, not included in page count)

[Name of Offeror]
[Address of Offeror]
[Phone Number and Email Address of Offeror]

Unique Entity Identifier (UEI) #: [UEI #]
CAGE code: [CAGE code]

RRPV 26-10-RAPID

[Title of Abstract]

[Offeror] certifies that, if selected for selected for an Award, the Offeror will abide by the terms and conditions of the RRPV Base Agreement.

[A proprietary data disclosure statement if proprietary data is included. Sample: This Abstract includes data that shall not be disclosed outside the RRPV Consortium Management Firm and the Government and shall not be duplicated, used, or disclosed, in whole or in part, for any purpose other than to evaluate this Abstract and negotiate any subsequent award. If, however, an award agreement is a result of, or in connection with, the submission of this data, the RRPV Consortium Management Firm and the Government shall have the right to duplicate, use, or disclose these data to the extent provided in the resulting agreement. This restriction does not limit the RRPV Consortium Management Firm and the Government's right to use the information contained in these data if they are obtained from another source without restriction. The data subject to this restriction is (clearly identify) and contained on pages (insert page numbers).]

[Title of Abstract]

1. **Executive Summary**
   - Provide the background and the Offeror's understanding of the problem.
   - Provide a description of the technology/process.
   - Emphasize how the proposed technology/process meets the overall objective specified in this RPP.

2. **Technical Approach**
   - Provide a clear description of the approach to solving the problem. Include relevant background/ preliminary data to demonstrate the maturity of your approach and advantages over current methods. Note: References are excluded from the page limit. There is no required format for included references.
   - Preliminary data [non-clinical and/or clinical] that support the feasibility of the proposed technology solution **must** be included.

3. **Teaming/Subcontractors**
   - High-level description of partnerships or collaborations that may be of use when developing this process/technology.

4. **Facilities and Personnel Qualification**
   - Provide high-level qualifications and expertise of the key personnel and organizations associated with the proposed solution. *Do not include resumes in Stage 1 submissions*
   - Provide brief descriptions of key past performance(s) that demonstrate relevance to the program objective and solution requirements.
   - Identify key facilities, equipment, and other resources relevant for the solution being proposed.

5. **Period of Performance/Schedule *(0.5 pg. limit, not included in page count)***
   - Identify the proposed Period of Performance (PoP) in months and describe the overall schedule.

6. **Budget Estimation *(0.5 pg. limit, not included in page count)***
   - Provide rough order of magnitude (ROM) estimate in a table and any pertinent assumptions for the proposed work.
   - Include rough estimates of overall labor cost and labor hours, material/equipment, other direct costs, indirect costs, as well as subcontractor costs (including similar detail).

7. **Data Rights Assertions *(as needed, not included in page count)***
   - It is anticipated that anything delivered under this proposed effort would be delivered to the Government with unlimited data rights. If this is not the intent, then you should discuss any restricted data rights associated. If applicable, complete the below table for any items to be furnished to the Government with restrictions. *An example is provided.*

This section is not part of the page count.

Technical Data or Computer Software to be Furnished with Restrictions	Basis for Assertion	Asserted Rights	Name of Organization Asserting Restrictions	Deliverables Affected

Quad Chart Template

Your quad chart must contain the following information and be positioned in a landscape view.
Any quad chart submitted that exceeds the one-page limit will not be read or evaluated.

PROJECT TITLE, RPP#, TECHNICAL/ADMINISTRATIVE POC (NAME, EMAIL, PHONE), COMPANY NAME & ADDRESS

Proposal Information	**Supporting Content and Project Planning Information**
Objective: Clear, concise (two to three sentences) description of the objectives and methodologies of the effort. Description of effort: A bullet list (2-3) of the primary scientific challenges being addressed	Picture or Graphic that Illustrates the research or concept (e.g., data figures, molecule illustrations or processes)
Benefits of Proposed Technology: Challenges: Maturity of Technology:	Bullet list of the major goals/milestones by: Project Year Proposed Funding (Rough Order of Magnitude Estimate)